UniProtKB/Swiss-Prot O14520: Variant p.Gly264Val

Aquaporin-7
Gene: AQP7
Feedback?

Variant information Variant position:

264 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

LB/B The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Glycine (G) to Valine (V) at position 264 (G264V, p.Gly264Val). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from glycine (G) to medium size and hydrophobic (V) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

-3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Polymorphism:

Genetic variations in AQP7 are responsible for changes in glycerol release during exercise and define the glycerol quantitative trait locus (GLYCQTL) [MIM:614411]. Additional information on the polymorphism described.
Variant description:

Affects water and glycerol transport. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs62542743 [ dbSNP | Ensembl ]

Sequence information Variant position:

264 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

342 The length of the canonical sequence.
Location on the sequence:

KQVFSNGENWWWVPVVAPLL G AYLGGIIYLVFIGSTIPREP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         KQVFSNGENWWWVPVVAPLLGAYLGGIIYLVFIGSTIPREP

Mouse                         KQVFRAGNNWWWVPVVAPLLGAYLGGIVYLGLIHPSIPQDP

Rat                           KKVFSAGNNWWWVPVVAPLLGAYLGGIVYLGLIHAGIP--P

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 342	Aquaporin-7
Topological domain	236 – 342	Extracellular
Alternative sequence	248 – 342	SNGENWWWVPVVAPLLGAYLGGIIYLVFIGSTIPREPLKLEDSVAYEDHGITVLPKMGSHEPTISPLTPVSVSPANRSSVHPAPPLHESMALEHF -> RYCPCPGPFL. In isoform 2.
Helix	256 – 278

Literature citations
Human aquaporin adipose (AQPap) gene. Genomic structure, promoter analysis and functional mutation.
Kondo H.; Shimomura I.; Kishida K.; Kuriyama H.; Makino Y.; Nishizawa H.; Matsuda M.; Maeda N.; Nagaretani H.; Kihara S.; Kurachi Y.; Nakamura T.; Funahashi T.; Matsuzawa Y.;
Eur. J. Biochem. 269:1814-1826(2002)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; INVOLVEMENT IN GLYCQTL; VARIANTS CYS-12; LEU-59 AND VAL-264; CHARACTERIZATION OF VARIANT VAL-264; FUNCTION; SUBCELLULAR LOCATION; Adipose tissue expression of the glycerol channel aquaporin-7 gene is altered in severe obesity but not in type 2 diabetes.
Ceperuelo-Mallafre V.; Miranda M.; Chacon M.R.; Vilarrasa N.; Megia A.; Gutierrez C.; Fernandez-Real J.M.; Gomez J.M.; Caubet E.; Fruhbeck G.; Vendrell J.;
J. Clin. Endocrinol. Metab. 92:3640-3645(2007)
Cited for: VARIANT VAL-264;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.